Quantum BioPharma Ltd. Clarifies Misinformation Regarding Name Change and RTO

Quantum BioPharma Ltd. (NASDAQ: QNTM) has taken a firm stance against the spread of misinformation regarding its corporate identity and financial dealings. Recent rumors on social media and stock trading platforms suggested that Quantum BioPharma had changed its name to Unbuzzd and was engaged in a reverse takeover (RTO) with Unbuzzd Wellness Inc. The company has categorically denied these claims, clarifying that no such name change or RTO transaction has occurred.

The confusion appears to have stemmed from a press release dated May 29, 2025, which detailed Quantum BioPharma's financial interests in Unbuzzd. Quantum BioPharma is indeed Unbuzzd's largest shareholder and debt holder, with ownership of 200 million shares, a 7% royalty agreement on revenue up to $250 million, and a warrant that could increase its stake to 25%. Additionally, Quantum BioPharma has provided Unbuzzd with a $1.3 million loan at a 10% interest rate over three years. Despite these financial ties, the two companies operate independently.

Unbuzzd, under the leadership of former Coca-Cola executive John Duffy and former Celsius Holdings CEO Gerry David, is reportedly gearing up for a potential initial public offering (IPO), with MNP LLP conducting PCAOB audits in preparation. Meanwhile, Quantum BioPharma has announced its intention to settle a $20,930 debt with two vendors by early June, further demonstrating its commitment to transparent and responsible financial management.

This clarification is crucial for investors and stakeholders who rely on accurate information to make informed decisions. The spread of misinformation can lead to unnecessary volatility in the stock market and undermine investor confidence. Quantum BioPharma's prompt response serves as a reminder of the importance of verifying information through official channels before acting on it.

The implications of this announcement extend beyond the immediate correction of false rumors. It highlights the challenges companies face in the digital age, where misinformation can spread rapidly and have tangible effects on stock prices and investor perceptions. Quantum BioPharma's situation underscores the need for vigilance and clear communication from corporations to protect their stakeholders' interests.